Head-To-Head Review: BeOne Medicines (NASDAQ:ONC) versus CytoDyn (OTCMKTS:CYDY)

CytoDyn (OTCMKTS:CYDY) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, dividends, analyst recommendations, earnings and profitability.

Profitability

This table compares CytoDyn and BeOne Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CytoDyn	N/A	N/A	-175.37%
BeOne Medicines	1.38%	5.52%	3.17%

Institutional & Insider Ownership

5.1% of CytoDyn shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 1.0% of CytoDyn shares are held by company insiders. Comparatively, 6.6% of BeOne Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

CytoDyn has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for CytoDyn and BeOne Medicines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoDyn	0	0	0	0	0.00
BeOne Medicines	1	1	13	0	2.80

BeOne Medicines has a consensus price target of $379.07, suggesting a potential upside of 9.43%. Given BeOne Medicines’ stronger consensus rating and higher possible upside, analysts plainly believe BeOne Medicines is more favorable than CytoDyn.

Valuation & Earnings

This table compares CytoDyn and BeOne Medicines”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoDyn	N/A	N/A	$3.74 million	($0.03)	-8.13
BeOne Medicines	$3.81 billion	9.97	-$644.79 million	$0.51	679.25

CytoDyn has higher earnings, but lower revenue than BeOne Medicines. CytoDyn is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Summary

BeOne Medicines beats CytoDyn on 11 of the 13 factors compared between the two stocks.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.